☆ 4.5 Review

Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis

MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Review Pharmacology & Pharmacy

Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers

Juan Jin et al.

Summary: Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer, and targeted therapy with Sunitinib has become the main treatment option due to the lack of efficacy in radiation therapy and chemotherapy. However, many patients develop resistance to Sunitinib within months of therapy. In this review, we discuss the molecular mechanisms of Sunitinib resistance, strategies to overcome it, and potential predictive biomarkers.

DRUG RESISTANCE UPDATES (2023)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Pharmacology & Pharmacy

New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers

Yu He et al.

Summary: Sorafenib is an effective drug for RCC treatment, but only a small number of patients benefit from it, and sorafenib resistance is increasing. The molecular mechanisms of sorafenib resistance in RCC are not completely understood at present.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection

Review Oncology

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Huan Deng et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Article Oncology

Sunitinib versus sorafenib for patients with advanced renal cell carcinoma with renal impairment before the immune-oncology therapy era

Tatsuya Takayama et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

Hiroki Ishihara et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

Wen Cai et al.

CHINESE JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

Hai-Liang Zhang et al.

BMC CANCER (2017)

Add to Collection

Article Oncology

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis

Xinan Sheng et al.

ONCOTARGET (2016)

Add to Collection

Review Oncology

Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)

V. Launay-Vacher et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Urology & Nephrology

EAU Guidelines on Renal Cell Carcinoma: 2014 Update

Borje Ljungberg et al.

EUROPEAN UROLOGY (2015)

Add to Collection

Article Urology & Nephrology

Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma

Matteo Santoni et al.

JOURNAL OF UROLOGY (2015)

Add to Collection

Article Oncology

Height and kidney cancer risk: a meta-analysis of prospective studies

Sudong Liang et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Real World Treatment of Metastatic Renal Cell Carcinoma in a Joint Community-Academic Cohort: Progression-Free Survival Over Three Lines of Therapy

Michael R. Harrison et al.

CLINICAL GENITOURINARY CANCER (2013)

Add to Collection

Article Oncology

Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients

Antonin Levy et al.

EUROPEAN JOURNAL OF CANCER (2013)

Add to Collection

Article Oncology

Sorafenib and sunitinib for elderly patients with renal cell carcinoma

Olfa Derbel Miled et al.

JOURNAL OF GERIATRIC ONCOLOGY (2013)

Add to Collection

Article Oncology

Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma

Seong Joon Park et al.

CHEMOTHERAPY (2012)

Add to Collection

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Article Oncology

Frequent Dose Interruptions are Required for Patients Receiving Oral Kinase Inhibitor Therapy for Advanced Renal Cell Carcinoma

David B. T. La Vine et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)

Add to Collection

Review Urology & Nephrology

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review

Toni K. Choueiri et al.

BJU INTERNATIONAL (2010)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Andreas Stang

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)

Add to Collection

Article Oncology

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

Bernard Escudier et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Oncology

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

Martin E. Gore et al.

LANCET ONCOLOGY (2009)

Add to Collection

Review Oncology

Sorafenib and Sunitinib

AeRang Kim et al.

ONCOLOGIST (2009)

Add to Collection

Review Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

PLOS MEDICINE (2009)

Add to Collection

Review Pharmacology & Pharmacy

Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer

Cheryl A. Grandinetti et al.

PHARMACOTHERAPY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.